Monthly Archives: June 2016

The Cancer Moonshot Summit: A Day For Our Nation To Reflect And Commit To What We Can Accomplish To Make This Cancer’s Last Century

Cancer Moonshot Summit.

Who would have imagined five short months ago that on this special day, almost 300 cancer centers and programs in every state attended by over 6000 leaders in cancer care and research, patients, advocates, and many others would have come together to commit themselves to doing what needs to be done—by everyone—to make this cancer’s last century?

Yet that is exactly what happened. President Obama made the declaration in his recent State of the Union address, put Vice President Biden in charge, and there has been no looking back. It is truly an amazing day in the annals of cancer care.

I was honored to be part of the program at the MD Anderson Cancer Center, hosted by the Center’s President Ronald DePinho MD. We were joined by hundreds of participants for two and one half hours of discussions focused on what all of us can do to move this effort forward. And among the speakers was Houston Texans’ defensive end, Devon Still, who shared with a hushed audience about his young daughter’s journey with neuroblastoma—and challenged all of us to reach out to communities to increase awareness about prevention, early detection and … Continue reading →

We Are Beginning To Realize The Promise Of Cell Free DNA In Cancer Care

Right now, when we want to know everything we can about a tumor, we do surgery: a biopsy to take a sample of it and look at it under a microscope and determine as best we can how to treat it. But what if instead you could get a blood test, and learn even more. That’s the promise of the relatively new science of what is called cell free DNA (cfDNA). It holds the hope of helping us better understand cancer, its behavior in our bodies over time, and even offering clues on how to better treat cancer in ways we would never have imagined even a few short years ago.

It was an important area of discussion at the American Society of Clinical Oncology meeting this week. It’s a meeting where, every year, we get a sense of the future of cancer treatment before it becomes a reality. From genomics, to immunotherapy, to targeted therapies–you name it—promising areas appear on the scene, then either become part of our reality or lose luster as the process unfolds over the course of several ASCO annual meetings. This year, several studies presented on the topic of the so-called “liquid biopsy” illustrate how … Continue reading →

Aromatase Inhibitors To Prevent Breast Cancer Recurrence: How Much Treatment Is Enough Treatment?

Here at the annual meeting of the American Society of Clinical Oncology in Chicago, we see results of eagerly awaited clinical trials that have involved hundreds or even thousands of patients, millions of dollars, and years of hard work and analysis. The results can be a success; they may fail; but quite often fall somewhere in between. And even when successful, the results may not be as clear cut as one would like.

Such is the case with an important trial whose results came were reported at this meeting and simultaneously published in the New England Journal of Medicine about the use of aromatase inhibitors (AI) in post-menopausal women with breast cancer. As is so often the case, the researchers are highly regarded, the study well designed—but even with all the best efforts possible, left open are some extremely difficult questions.… Continue reading →

Precision/Personalized Medicine: Can We Afford Our Success?

Here at the at annual meeting of the American Society of Clinical Oncology in Chicago, we are beginning to see the future of cancer therapy—and it raises a provocative question: will precision medicine become so precise, we risk turning off the much-needed investment of human, intellectual and financial capital that keeps progress flowing?

The sheer number of new drugs and new combinations of drugs being reported here at the world’s biggest, and most relevant cancer conference is staggering. Not all of them are ready for prime time, and some may never be successful in the clinic for large numbers of patients, but it is clear the era of old fashioned chemotherapy is diminishing and newer forms of therapies (targeted and immunotherapies among others) are on the rapid ascent.

But with progress, it’s becoming clear that a changing paradigm in cancer care that was predicted a number of years ago is now coming to life.… Continue reading →

Why Don’t We Pay As Much Attention To Prevention And Better Cancer Care As We Do To The Next Great New Cancer Drug?

The largest and most important cancer meeting of the year, the American Society of Clinical Oncology Annual Meeting, is going on this weekend in Chicago, and that’s a good time for one to give some thought to the broader topic of what has happened in cancer care over the past year.

But as I have started sitting in the sessions listening to stories of progress and new breaking research on truly innovative therapeutics and diagnostics, a lingering, somewhat troubling thought has persisted. I find myself coming back to a very basic question: we are spending billions—yes, billions—on new approaches to detecting and treating cancer. But we are spending nowhere near that amount on the fundamental “blocking and tackling” in cancer: the tactics that can help prevent the disease and –by applying what we know—can reduce its deadly toll.

What has been on my mind is a chance meeting I had with a lady during my recent travels. She saw the American Cancer Society lapel pin that I wear on my suit jacket and asked me if we are making progress in treating cancer. I answered her question with my usual cautious optimism (for some diseases, significant progress; for others, … Continue reading →